hydroxychloroquine has been researched along with Lymphohistiocytosis, Hemophagocytic in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Lymphohistiocytosis, Hemophagocytic: A group of related disorders characterized by LYMPHOCYTOSIS; HISTIOCYTOSIS; and hemophagocytosis. The two major forms are familial and reactive.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| "Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China." | 1.56 | Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report. ( Bhatt, PJ; Narayanan, N; Radbel, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lipworth, B | 1 |
| Chan, R | 1 |
| Lipworth, S | 1 |
| RuiWen Kuo, C | 1 |
| Radbel, J | 1 |
| Narayanan, N | 1 |
| Bhatt, PJ | 1 |
| Cai, S | 1 |
| Sun, W | 2 |
| Li, M | 1 |
| Dong, L | 1 |
| Quintana-Ortega, C | 1 |
| Remesal, A | 1 |
| Ruiz de Valbuena, M | 1 |
| de la Serna, O | 1 |
| Laplaza-González, M | 1 |
| Álvarez-Rojas, E | 1 |
| Udaondo, C | 1 |
| Alcobendas, R | 1 |
| Murias, S | 1 |
| Shi, W | 1 |
| Duan, M | 1 |
| Jie, L | 1 |
| Vithoosan, S | 1 |
| Karunarathna, T | 1 |
| Shanjeeban, P | 1 |
| Piranavan, P | 1 |
| Matthias, T | 1 |
| Gamlaksha, D | 1 |
| Liyadipita, A | 1 |
| Kulatunga, A | 1 |
| Elqatni, M | 1 |
| Mekouar, F | 1 |
| Sekkach, Y | 1 |
| Elomri, N | 1 |
| Fatihi, J | 1 |
| Amezyane, T | 1 |
| Abouzahir, A | 1 |
| Ghafir, D | 1 |
| Keith, MP | 1 |
| Pitchford, C | 1 |
| Bernstein, WB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19[NCT04560205] | Phase 1 | 50 participants (Anticipated) | Interventional | 2020-05-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Lymphohistiocytosis, Hemophagocytic
| Article | Year |
|---|---|
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
7 other studies available for hydroxychloroquine and Lymphohistiocytosis, Hemophagocytic
| Article | Year |
|---|---|
Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Angiotensin-Converting Enzyme Inhi | 2020 |
Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Azi | 2020 |
Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antivira | 2021 |
A successful treatment of severe systemic lupus erythematosus caused by occult pulmonary infection-associated with hemophagocytic syndrome: A case report.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Blood Cell Count; Bone Marrow Examination; Cilas | 2018 |
Kikuchi-Fujimoto disease associated with systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Bone Marrow; Glucocortico | 2019 |
[Haemophagocytic syndrome as a complication of acute pancreatitis during systemic lupus erythematosus].
Topics: Abdomen, Acute; Autoantibodies; Female; Gingival Hemorrhage; Humans; Hydroxychloroquine; Lupus Eryth | 2012 |
Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus.
Topics: Alemtuzumab; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Drug Th | 2012 |